STIM

Neuronetics, Inc.

14 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 29

Approval of 2026 Equity Incentive Plan allows for further share-based compensation.

capital raise

60%

neutralMay 29

Re-election of the board of directors with varying levels of shareholder support.

management change

30%

bearishMay 29

Significant minority opposition to equity plan suggests high perceived dilution risk.

dilution risk

70%

neutralMay 22

Extension of interim financial officer role via amended consulting agreement.

management change

40%

bearishMay 22

Increase in fixed monthly consulting spend for financial oversight.

margin compression

20%

neutralMay 22

Extension of interim financial officer role via amended consulting agreement.

management change

40%

bearishMay 22

Increase in fixed monthly consulting spend for financial oversight.

margin compression

20%

neutralMay 22

Extension of interim financial officer role via amended consulting agreement.

management change

40%

bearishMay 22

Increase in fixed monthly consulting spend for financial oversight.

margin compression

20%

neutralMay 22

Extension of interim financial officer role via amended consulting agreement.

management change

40%

bearishMay 22

Increase in fixed monthly consulting spend for financial oversight.

margin compression

20%

neutralMay 22

Extension of interim financial officer role via amended consulting agreement.

management change

40%

bearishMay 22

Increase in fixed monthly consulting spend for financial oversight.

margin compression

20%

neutralMay 22

Extension of interim financial officer role via amended consulting agreement.

management change

40%

bearishMay 22

Increase in fixed monthly consulting spend for financial oversight.

margin compression

20%

bullishMay 5

Total revenue increased 8% year-over-year to $34.5 million.

earnings beat

60%

bearishMay 5

Gross margin declined from 49.2% to 46.9% due to shift in revenue mix.

margin compression

40%

bearishMay 5

Ongoing use of ATM program and issuance of warrants to manage liquidity.

dilution risk

70%

neutralMay 5

Amended credit facility covenants to modify revenue and liquidity requirements through 2026/2027.

debt restructure

50%

bullishMay 5

Total revenue increased 8% year-over-year to $34.5 million.

earnings beat

60%

bearishMay 5

Gross margin declined from 49.2% to 46.9% due to shift in revenue mix.

margin compression

40%

bearishMay 5

Ongoing use of ATM program and issuance of warrants to manage liquidity.

dilution risk

70%

neutralMay 5

Amended credit facility covenants to modify revenue and liquidity requirements through 2026/2027.

debt restructure

50%

bullishMay 5

Total revenue increased 8% year-over-year to $34.5 million.

earnings beat

60%

bearishMay 5

Gross margin declined from 49.2% to 46.9% due to shift in revenue mix.

margin compression

40%

bearishMay 5

Ongoing use of ATM program and issuance of warrants to manage liquidity.

dilution risk

70%

neutralMay 5

Amended credit facility covenants to modify revenue and liquidity requirements through 2026/2027.

debt restructure

50%

bullishMay 5

Total revenue increased 8% year-over-year to $34.5 million.

earnings beat

60%

bearishMay 5

Gross margin declined from 49.2% to 46.9% due to shift in revenue mix.

margin compression

40%

bearishMay 5

Ongoing use of ATM program and issuance of warrants to manage liquidity.

dilution risk

70%

neutralMay 5

Amended credit facility covenants to modify revenue and liquidity requirements through 2026/2027.

debt restructure

50%

bullishMay 5

Total revenue increased 8% year-over-year to $34.5 million.

earnings beat

60%

bearishMay 5

Gross margin declined from 49.2% to 46.9% due to shift in revenue mix.

margin compression

40%

bearishMay 5

Ongoing use of ATM program and issuance of warrants to manage liquidity.

dilution risk

70%

neutralMay 5

Amended credit facility covenants to modify revenue and liquidity requirements through 2026/2027.

debt restructure

50%

bullishMay 5

Total revenue increased 8% year-over-year to $34.5 million.

earnings beat

60%

bearishMay 5

Gross margin declined from 49.2% to 46.9% due to shift in revenue mix.

margin compression

40%

bearishMay 5

Ongoing use of ATM program and issuance of warrants to manage liquidity.

dilution risk

70%

neutralMay 5

Amended credit facility covenants to modify revenue and liquidity requirements through 2026/2027.

debt restructure

50%

bullishMay 5

Total revenue increased 8% year-over-year to $34.5 million.

earnings beat

60%

bearishMay 5

Gross margin declined from 49.2% to 46.9% due to shift in revenue mix.

margin compression

40%

bearishMay 5

Ongoing use of ATM program and issuance of warrants to manage liquidity.

dilution risk

70%

neutralMay 5

Amended credit facility covenants to modify revenue and liquidity requirements through 2026/2027.

debt restructure

50%

Filing History

8-KMay 29, 2026

The 8-K filing details a successful but contentious annual meeting where Neuronetics passed key proposals, including its new equity plan and board elections. While the company technically achieved the necessary approvals to proceed with its strategic roadmap, the narrow margins and high volume of dissenting votes highlight a precarious relationship with its shareholders. Investors are now weighing the potential for accelerated growth against the looming risks of dilution and governance instability.

8-KMay 22, 2026

The filing details an amendment to the consulting agreement of Francis X. Brown III, shifting his compensation to a monthly retainer and extending his role as Interim PAO. While the company frames this as a stabilizing move to ensure continuity, the lack of a concrete timeline for a permanent hire introduces uncertainty. Investors must weigh the benefit of professional interim oversight against the risks associated with a prolonged executive vacancy in the finance department.

10-QMay 5, 2026

The Q1 2026 filing presents a stark contrast between operational momentum and financial fragility. On one hand, the company is growing its revenue and successfully integrating a clinic-based service model that diversifies its income streams. On the other hand, the balance sheet is under extreme pressure, with a looming covenant breach and a cash balance that has halved since the end of 2025. The company is essentially racing to achieve operational scale and profitability before its credit window closes. Investors are left to weigh the potential of a high-growth mental health platform against the immediate risk of a lender-driven liquidation. While the reduction in cash burn and the increase in clinic revenue are positive signals, they are currently outweighed by the 'substantial doubt' regarding the company's ability to continue as a going concern. The outcome for shareholders will likely depend on the company's ability to either secure further covenant waivers or accelerate revenue growth enough to satisfy the Perceptive Facility requirements by early 2027.